title: Soluble interleukin 2 receptor in atopic eczema.
abstract: OBJECTIVE
  To determine whether serum soluble interleukin 2 receptor concentrations are related to disease activity in atopic eczema.
  
  
  METHODS
  Single cohort longitudinal study with controls.
  
  
  METHODS
  Outpatient and general medicine departments in secondary referral centre.
  
  
  METHODS
  Of 15 patients aged 17-57 with severe atopic eczema, all with acute exacerbations of disease, 13 were admitted to hospital and two treated as outpatients until the skin lesions had resolved or greatly improved. Nineteen controls gave single blood samples.
  
  
  METHODS
  Daily skin dressing with betamethasone valerate (0.025%) and ichthammol paste and tubular dressings.
  
  
  METHODS
  Resolution of or considerable improvement in skin lesions.
  
  
  RESULTS
  Enzyme linked immunosorbent assays (ELISA) were used to measure serum soluble interleukin 2 receptor concentrations in blood samples taken on admission, at intervals subsequently, and on discharge. Clinical scores of disease activity were also made. Median concentrations on admission were significantly higher (770 U/ml) in the patients than the controls (300 U/ml). Concentrations fell significantly during treatment. In 25 assessments made at different times in 13 patients serum soluble interleukin 2 receptor concentration correlated significantly (R = 0.73) with clinical disease activity.
  
  
  CONCLUSIONS
  Cellular immunopathogenic mechanisms contribute to atopic eczema. Immune activation can be measured in atopic eczema by measurements of soluble interleukin 2 receptor, and this should facilitate assessment of response to treatment.
authors.affiliation: Department of Dermatology, University of Edinburgh.
authors.forename: G B
authors.initials: GB
authors.lastname: Colver
authors.forename: J A
authors.initials: JA
authors.lastname: Symons
authors.forename: G W
authors.initials: GW
authors.lastname: Duff
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001624:Betamethasone Valerate / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000276:immunology*; D003879:Dermatologic Agents / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D012606:Scotland
chemical_list: D003879:Dermatologic Agents; D015375:Receptors, Interleukin-2; D001624:Betamethasone Valerate